Drug Information

Drug General Information
Drug ID
D0PT2D
Former ID
DNC014700
Drug Name
MR-22388
Drug Type
Small molecular drug
Indication Discovery agent Investigative [526982]
Formula
C16H11NO3S
Canonical SMILES
COC1=C(C=C(C=C1)C2=CSC3=C2N4C=CC=C4C3=O)O
InChI
1S/C16H11NO3S/c1-20-13-5-4-9(7-12(13)18)10-8-21-16-14(10)17-6-2-3-11(17)15(16)19/h2-8,18H,1H3
InChIKey
IXGRUAKWRHZSAP-UHFFFAOYSA-N
PubChem Compound ID
9904289
Target and Pathway
Target(s) Tubulin beta Target Info Inhibitor [526982]
Tubulin Target Info Inhibitor [526982]
KEGG Pathway Phagosome
Gap junction
Pathogenic Escherichia coli infection
NetPath Pathway FSH Signaling Pathway
TCR Signaling Pathway
EGFR1 Signaling Pathway
PANTHER Pathway Cytoskeletal regulation by Rho GTPase
Huntington disease
Reactome Regulation of PLK1 Activity at G2/M Transition
Loss of Nlp from mitotic centrosomes
Recruitment of mitotic centrosome proteins and complexes
Loss of proteins required for interphase microtubule organization?from the centrosome
Anchoring of the basal body to the plasma membrane
WikiPathways Parkin-Ubiquitin Proteasomal System pathway
Pathogenic Escherichia coli infection
Mitotic G2-G2/M phases
References
Ref 526982J Med Chem. 2004 Mar 11;47(6):1448-64.Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents.
Ref 526982J Med Chem. 2004 Mar 11;47(6):1448-64.Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.